Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,608.18
    -1,612.02 (-3.21%)
     

  • CMC Crypto 200

    1,264.03
    -93.98 (-6.92%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

AL Amyloidosis Market Insights, Epidemiology, and Market Forecast to 2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan

Research and Markets
·5-min read

Dublin, Jan. 04, 2021 (GLOBE NEWSWIRE) -- The "AL Amyloidosis - Market Insights, Epidemiology, and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

This 'AL Amyloidosis - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the AL amyloidosis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

AL Amyloidosis Epidemiology

The AL Amyloidosis symptoms epidemiology division provides insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The incident cases of AL Amyloidosis in the 7MM will increase during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical and forecasted AL Amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis. The report includes the incident scenario of AL amyloidosis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

AL Amyloidosis Drug Chapters

The drug chapter segment of the AL Amyloidosis report encloses the detailed analysis of AL amyloidosis early-stage (Phase-I/II, II, and III) pipeline drugs. It also helps to understand the AL Amyloidosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

AL Amyloidosis Market Outlook

The AL amyloidosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted AL amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

This segment gives a thorough detail of AL Amyloidosis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

This section includes a glimpse of the AL amyloidosis market in 7MM. The market size of AL Amyloidosis in the seven major markets was found to be USD 887.3 Million in 2017.

AL Amyloidosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers the AL amyloidosis market uptake by drugs, patient uptake by therapies, and drug sales.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

AL Amyloidosis Pipeline Development Activities

The report provides insights into the therapeutic candidate in phase I/II, II, and III stages. It also analyses AL Amyloidosis key players involved in developing targeted therapeutics.

Major players include Janssen Pharmaceuticals, Caelum Biosciences, Oncopeptides AB, and Bristol Myers Squibb.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisitions and mergers, licensing, and patent details for AL Amyloidosis emerging therapies.

Key Topics Covered:

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 AL Amyloidosis: Market Overview at a Glance
5.1 Total Market Share (%) Distribution of AL Amyloidosis in 2017
5.2 Total Market Share (%) Distribution of AL Amyloidosis in 2030

6 AL Amyloidosis: Disease Overview
6.1 Introduction
6.2 Types of Amyloidosis
6.3 Etiology
6.4 Signs and Symptoms
6.5 Clinical Presentation
6.6 Pathophysiology
6.7 Prognosis
6.8 Diagnosis
6.8.1 Differential Diagnosis
6.8.2 Diagnostic guidelines
6.8.3 Diagnostic Algorithm

7 Epidemiology and Patient Population
7.1 Key Findings

8 7MM Epidemiology
8.1 Assumptions and rationale
8.2 Total cases of AL Amyloidosis in 7MM
8.3 United States
8.3.1 Total Incident cases of AL Amyloidosis in the United States
8.3.2 Gender-specific cases of AL Amyloidosis in the United States
8.3.3 Age-specific cases of AL Amyloidosis in the United States
8.1 EU5 Countries
8.2 Germany
8.3 France
8.4 Italy
8.5 Spain
8.6 UK
8.7 Japan

9 Treatment of AL Amyloidosis
9.1 Treatment Guidelines

10 Unmet needs

11 Emerging Therapies
11.1 Key competitors
11.2 Daratumumab: Janssen Pharmaceutical
11.2.1 Drug Description
11.2.2 Other Development Activities
11.2.3 Clinical Development
11.2.4 Safety and Efficacy
11.2.5 Product Profile
11.3 CAEL-101: Caelum Biosciences
11.4 Melflufen: Oncopeptides AB
11.5 Elotuzumab: Bristol-Myers Squibb
11.6 Other potential therapies
11.7 Evomela: Acrotech biopharma
11.8 Isatuximab: Sanofi

12 AL Amyloidosis: Seven Major Market Analysis
12.1 Key Findings
12.2 Market Size of AL Amyloidosis in the 7MM

13 Seven Major Market Outlook

14 United States Market Size

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

19 Case Study
19.1 Ptosis and macroglossia in a woman with systemic light-chain amyloidosis
19.2 Cardiac amyloidosis: A case report
19.3 One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/otihyd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900